168 results
8-K
EX-99.1
DMAC
DiaMedica Therapeutics Inc.
7 Aug 24
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
4:32pm
of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may
424B3
DMAC
DiaMedica Therapeutics Inc.
18 Jul 24
Prospectus supplement
5:28pm
or concern in the nature of trade.
This summary does not apply to a Holder, (i) that is a “financial institution” for purposes of the mark-to-market rules … is of a general nature only and is not, and is not intended to be, and should not be construed to be, legal or tax advice to any particular Holder
D
vzn2fb7o
2 Jul 24
$11.80 mm in equity, sold $11.80 mm, 10 investors
4:07pm
8-K
EX-10.1
fv6bwt00 dsb
26 Jun 24
DiaMedica Therapeutics Announces $11.8 Million
8:16am
8-K
EX-10.2
owpybwbs4c49k1lvot
26 Jun 24
DiaMedica Therapeutics Announces $11.8 Million
8:16am
8-K
EX-99.1
3fv4r6rzhd0
26 Jun 24
DiaMedica Therapeutics Announces $11.8 Million
8:16am
8-K
EX-99.2
uuoubifsqa
26 Jun 24
Regulation FD Disclosure
8:01am
8-K
bpvamm15t0d
26 Jun 24
Regulation FD Disclosure
8:01am
8-K
EX-10.1
klkxcf hl
23 May 24
Departure of Directors or Certain Officers
4:00pm
8-K
EX-99.1
5rck4s8ctyii3
8 May 24
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
4:30pm
8-K
EX-99.1
6m2aie7iyrwh86e raye
19 Mar 24
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
4:16pm
8-K
EX-99.1
827e3syj2kxi
13 Nov 23
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
4:52pm